UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity
UniQure (NASDAQ:QURE) is one of the most promising low-cost stocks to buy now. On February 6, UniQure reported positive updated data from its Phase I/IIa trial of AMT-191, which is a gene therapy for Fabry disease. All 11 patients across three different dose levels showed increased enzyme activity, with the longest-treated patient maintaining these high levels for over a year. Notably, the enzyme levels were significantly above normal ranges, showing a clear relationship between the dose received and the amount of enzyme produced.
The treatment allowed 6 out of the 11 patients to stop their regular enzyme replacement therapy/ERT after meeting specific clinical criteria. Even after stopping ERT, patients maintained stable levels of lyso-Gb3, the toxic substance that typically builds up in Fabry disease. This suggests that the one-time gene therapy could potentially replace the need for lifelong, bi-weekly infusions for some patients.
While the therapy shows promise, UniQure has paused new dosing in the mid- and high-dose groups to evaluate some safety findings. Two patients in the middle dose group experienced high liver enzyme levels that were classified as dose-limiting toxicities, though both responded to steroid treatment. Other previously reported serious events in the high-dose group included chest pain and a stroke, though some were determined to be unrelated to the study drug.
UniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases in the US.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crypto activity recovered in July, new liquidity still limited
Wall Street rises sharply, driven by soaring Microsoft stock
Ethereum outperforms Bitcoin as Bitmine buys 9,946 ETH

16 Billion "Blood-Stained Chips" Settled: Citadel Defuses the AI Crash Wave—Is This the End of Liquidation or the Start of a Domino Effect?
After the market confirmed that Situational Awareness no longer required disorderly selling, the supply from sellers sharply decreased, leading to simultaneous short covering and fundamental buying: South Korea's KOSPI surged by a record 17.9%, Samsung Electronics and SK Hynix soared approximately 28% and 30% respectively, and the Philadelphia Semiconductor Index also rebounded strongly.

